Last reviewed · How we verify
Chenix (CHENODIOL)
Chenix works by binding to the bile acid receptor, which increases the excretion of bile acids and helps dissolve gallstones.
Chenix (chenodiol) is a small molecule drug that targets the bile acid receptor. Originally developed and currently owned by Mirum, it was FDA-approved in 1983 for the treatment of calculus in the biliary tract. Chenix is an off-patent, generic medication with a half-life of 1.42 hours. It is used to dissolve gallstones by altering the composition of bile acids. As an off-patent medication, it is available from a single generic manufacturer.
At a glance
| Generic name | CHENODIOL |
|---|---|
| Sponsor | Mirum |
| Drug class | Bile Acid [EPC] |
| Target | Bile acid receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1983 |
Mechanism of action
Imagine your body's bile acids as a sticky liquid that helps digest food. Chenix helps change the way your body uses this liquid, making it less sticky and more likely to dissolve gallstones. This process helps to break down and remove gallstones from the biliary tract.
Approved indications
- Calculus in biliary tract
Common side effects
- diarrhea
- headache
- abdominal pain (including abdominal pain upper)
- constipation
- hypertension
- muscular weakness
- upper respiratory tract infection
Drug interactions
- Bile acid sequestering agents (e.g., cholestyramine, colestipol)
- Aluminum-based antacids
- Coumarin and its derivatives
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones). (PHASE4)
- Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 (PHASE2)
- A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (PHASE2)
- Intravenous Infusion of CAP-1002 in Patients With COVID-19 (PHASE2)
- A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX) (PHASE3)
- Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) (PHASE3)
- Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition (PHASE4)
- Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |